Safety of neuraminidase inhibitors for influenza

Research output: Contribution to journalReview articleResearchpeer-review

11 Citations (Scopus)
37 Downloads (Pure)

Abstract

Neuraminidase inhibitors, oseltamivir and zanamivir, are used for the treatment of, and protection from, influenza. The safety of these compounds has been assessed in systematic reviews. However, the data presented are somewhat limited by the paucity of good quality adverse event data available. The majority of safety outcomes are based on evidence from just one or two randomised controlled trials. The results of the systematic reviews suggest that neuraminidase inhibitors have a reasonable side effect and adverse effect profile if they are to be used to treat or protect patients against a life-threatening disease. However, if these compounds are to be prescribed in situations in which avoidance of inconvenience or minor discomfort is hoped for, then the balance of harms to benefits will be more difficult to judge.

Original languageEnglish
Pages (from-to)603-608
Number of pages6
JournalExpert Opinion on Drug Safety
Volume5
Issue number5
DOIs
Publication statusPublished - Sep 2006

Fingerprint

Neuraminidase
Human Influenza
Zanamivir
Oseltamivir
Safety
Randomized Controlled Trials
Therapeutics

Cite this

@article{90a286250b514bd683b7e9ba4e02d743,
title = "Safety of neuraminidase inhibitors for influenza",
abstract = "Neuraminidase inhibitors, oseltamivir and zanamivir, are used for the treatment of, and protection from, influenza. The safety of these compounds has been assessed in systematic reviews. However, the data presented are somewhat limited by the paucity of good quality adverse event data available. The majority of safety outcomes are based on evidence from just one or two randomised controlled trials. The results of the systematic reviews suggest that neuraminidase inhibitors have a reasonable side effect and adverse effect profile if they are to be used to treat or protect patients against a life-threatening disease. However, if these compounds are to be prescribed in situations in which avoidance of inconvenience or minor discomfort is hoped for, then the balance of harms to benefits will be more difficult to judge.",
author = "Mark Jones and {Del Mar}, Chis",
note = "reproduces with permission From: Crone, Jane [Jane.Crone@informa.com] Sent: Thursday, 14 September 2006 11:32 PM To: Yvonne Auld Subject: RE: Requesting Permission to Archive in Bond University's Institutional Repository Follow Up Flag: Follow up Flag Status: Red Dear Yvonne Thank you for your enquiry. In this instance we give permission to use the aforementioned article as described in your email below, including acknowledgement to 'Informa Healthcare, Informa UK Ltd' as publisher and link to our website www.expertopin.com . Regards Jane Crone Administrator - Expert Opinion Informa Healthcare Telephone House 69-77 Paul Street London EC2A 4LQ Tel: +44 (0)20 7017 6874 Fax: +44 (0)20 7017 7667 Email: jane.crone@informa.com -----Original Message----- From: Yvonne Auld [mailto:yauld@bond.edu.au] Sent: 29 August 2006 08:28 To: Crone, Jane Subject: Requesting Permission to Archive in Bond University's Institutional Repository Attention: Permissions Manager Requesting Permission to Archive in Bond University{\^a}€™s Institutional Repository Permission is requested on behalf of author Professor Chris Del Mar to deposit an electronic version of an article from Expert Opinion on Drug Safety in Bond University{\^a}€™s Institutional Repository e-publications@bond for educational and research purposes. The institutional repository, e-publications@bond is a non profit service designed to showcase research and scholarship emanating from Bond University and facilitate open access for educational and research purposes. No charge is made for the use of any of the material deposited. Permission is requested to archive the following article: Jones M, Del Mar C. Safety of neuraminidase inhibitors for influenza. Expert Opin Drug Saf 2006;5:603-8. If this request is approved we would acknowledge you as the publisher and link to your site as required. If permission is granted, could we post an exact electronic copy of the published version of the document? Could you advise if you have a generic permissions policy regards author archiving in their institutional repositories? e-publications@bond is maintained by the Bond University Library. Thank you for your assistance in this matter. Yvonne Auld",
year = "2006",
month = "9",
doi = "10.1517/14740338.5.5.603",
language = "English",
volume = "5",
pages = "603--608",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare USA",
number = "5",

}

Safety of neuraminidase inhibitors for influenza. / Jones, Mark; Del Mar, Chis.

In: Expert Opinion on Drug Safety, Vol. 5, No. 5, 09.2006, p. 603-608.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Safety of neuraminidase inhibitors for influenza

AU - Jones, Mark

AU - Del Mar, Chis

N1 - reproduces with permission From: Crone, Jane [Jane.Crone@informa.com] Sent: Thursday, 14 September 2006 11:32 PM To: Yvonne Auld Subject: RE: Requesting Permission to Archive in Bond University's Institutional Repository Follow Up Flag: Follow up Flag Status: Red Dear Yvonne Thank you for your enquiry. In this instance we give permission to use the aforementioned article as described in your email below, including acknowledgement to 'Informa Healthcare, Informa UK Ltd' as publisher and link to our website www.expertopin.com . Regards Jane Crone Administrator - Expert Opinion Informa Healthcare Telephone House 69-77 Paul Street London EC2A 4LQ Tel: +44 (0)20 7017 6874 Fax: +44 (0)20 7017 7667 Email: jane.crone@informa.com -----Original Message----- From: Yvonne Auld [mailto:yauld@bond.edu.au] Sent: 29 August 2006 08:28 To: Crone, Jane Subject: Requesting Permission to Archive in Bond University's Institutional Repository Attention: Permissions Manager Requesting Permission to Archive in Bond University’s Institutional Repository Permission is requested on behalf of author Professor Chris Del Mar to deposit an electronic version of an article from Expert Opinion on Drug Safety in Bond University’s Institutional Repository e-publications@bond for educational and research purposes. The institutional repository, e-publications@bond is a non profit service designed to showcase research and scholarship emanating from Bond University and facilitate open access for educational and research purposes. No charge is made for the use of any of the material deposited. Permission is requested to archive the following article: Jones M, Del Mar C. Safety of neuraminidase inhibitors for influenza. Expert Opin Drug Saf 2006;5:603-8. If this request is approved we would acknowledge you as the publisher and link to your site as required. If permission is granted, could we post an exact electronic copy of the published version of the document? Could you advise if you have a generic permissions policy regards author archiving in their institutional repositories? e-publications@bond is maintained by the Bond University Library. Thank you for your assistance in this matter. Yvonne Auld

PY - 2006/9

Y1 - 2006/9

N2 - Neuraminidase inhibitors, oseltamivir and zanamivir, are used for the treatment of, and protection from, influenza. The safety of these compounds has been assessed in systematic reviews. However, the data presented are somewhat limited by the paucity of good quality adverse event data available. The majority of safety outcomes are based on evidence from just one or two randomised controlled trials. The results of the systematic reviews suggest that neuraminidase inhibitors have a reasonable side effect and adverse effect profile if they are to be used to treat or protect patients against a life-threatening disease. However, if these compounds are to be prescribed in situations in which avoidance of inconvenience or minor discomfort is hoped for, then the balance of harms to benefits will be more difficult to judge.

AB - Neuraminidase inhibitors, oseltamivir and zanamivir, are used for the treatment of, and protection from, influenza. The safety of these compounds has been assessed in systematic reviews. However, the data presented are somewhat limited by the paucity of good quality adverse event data available. The majority of safety outcomes are based on evidence from just one or two randomised controlled trials. The results of the systematic reviews suggest that neuraminidase inhibitors have a reasonable side effect and adverse effect profile if they are to be used to treat or protect patients against a life-threatening disease. However, if these compounds are to be prescribed in situations in which avoidance of inconvenience or minor discomfort is hoped for, then the balance of harms to benefits will be more difficult to judge.

UR - http://www.scopus.com/inward/record.url?scp=33747499143&partnerID=8YFLogxK

U2 - 10.1517/14740338.5.5.603

DO - 10.1517/14740338.5.5.603

M3 - Review article

VL - 5

SP - 603

EP - 608

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 5

ER -